news
-
5 October 2020Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today announced survey results of 137 patients previously implanted with the Medtronic InterStim II ™ that are now being treated with the Axonics r-SNM System.
In the survey, Axonics asked patients about Axonics SNM therapy and to make comparisons to their prior experience with InterStim II. Key findings of the survey include:
Patients prefer Axonics therapy over InterStim II
92% of patients that have been treated with both systems would choose Axonics over InterStim if they were asked to decide about the therapy again
83% of patients would recommend Axonics over InterStim to a friend. Only 5% of patients stated they would recommend InterStim over Axonics
78% of patients said that the recommendation of their physician was key to their decision to switch
Patients that prefer Axonics over InterStim cited the following as the most important features of the Axonics System:
15+ year life; fewer repeat procedures
MRI compatibility
Easy to use remote controlPatients feel they are doing better with Axonics compared to InterStim II
71% of patients said they are having a better overall experience with the Axonics System compared to InterStim. Only 11% of patient said they preferred the non-rechargeable InterStim
53% of patients are experiencing better symptom relief with Axonics than InterStim, while 38% stated they are experiencing about the same level of symptom relief
Patients are finding it easy to recharge the Axonics System and use the patient remote control
91% of patients are not bothered by recharging their Axonics System
81% of patients stated that recharging the Axonics System is easy despite only having experience with a non-rechargeable implant previously
82% of patients rated their Axonics patient remote control experience as “Excellent” or “Good.” Features of the Axonics remote control cited as most beneficial compared to InterStim include:
Easier to make adjustments to stimulation level
Easy to check status of stimulation
Comfortable one-handed use
Smaller sizeRaymond W. Cohen, Axonics CEO, said, "We specifically surveyed these particular patients because they have a direct basis of comparison and can provide unbiased feedback on both devices. The fact that 92% of patients that have been treated with both systems would choose Axonics over InterStim is compelling and underscores that patients want an implant that is long-lived, efficacious and easy to interface with. It is also clear that physicians have great influence over decisions patients make. This informs us that Axonics has to continue to make physicians aware that there are significant and distinct advantages of our r-SNM System over InterStim II which, as of today, is still being implanted despite employing voltagecontrolled technology that was originally engineered over 20 years ago.”
Cohen continued, "Delivering a superior experience to patients has been the key focus of our product development initiatives since Axonics’ founding. We remain confident that our keen focus on innovation, enhancing the patient experience, and increasing awareness of SNM therapy will drive significant market expansion in the years ahead."
Related
Axonics® Provides Update on Inter Partes Review Proceedings
Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator
Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study
NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder
Axonics® Reports Second Quarter 2020 Results
Axonics® Announces 2-Year Topline Clinical Results from ARTISAN-SNM Pivotal Study
Axonics® Reports Preliminary Second Quarter 2020 Revenue
Axonics® Receives FDA Approval for 3T Full-Body MRI Scans
Axonics® Reports First Quarter 2020 Results
Axonics® Announces Fourth Quarter and Fiscal 2019 Financial Results
Axonics® Sacral Neuromodulation System Receives Reimbursement Approval in Germany
Axonics® Announces FDA Approval of Enhanced Neurostimulator Programmer
Axonics® Announces Preliminary Fourth Quarter and Full Year 2019 Revenue
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sanford Health Now Implanting Axonics® Sacral Neuromodulation Systems
Axonics® Announces Pricing of Public Offering of Common Stock
Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System
Axonics® Announces Second Quarter 2019 Financial Results and Operational Update
Axonics® Announces 1-Year Top-Line Clinical Results from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of ARTISAN Clinical Study Results in the Journal of Urology
Axonics® Announces First Quarter 2019 Financial Results and Operational Update
Axonics® Announces Fourth Quarter and Full Year 2018 Financial Results and Operational Update
Axonics® Announces Positive Top-Line Clinical Data from its ARTISAN-SNM Pivotal Study
Axonics® Announces Publication of NICE Briefing
Axonics® Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Axonics® Receives Health Canada Approval for its Sacral Neuromodulation External Trial System
Axonics® Announces Closing of Initial Public Offering of Common Stock
Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock
Axonics® Receives Technology Innovation Award from Medtech Insight
Axonics® Receives CE Mark for its Sacral Neuromodulation External Trial System
Axonics® Completes Enrollment of U.S. FDA Pivotal Study for its Sacral Neuromodulation System
Axonics Announces $40 Million Financing
Axonics® Sacral Neuromodulation System Receives Marketing Approval in Australia
Axonics® Granted Seven New U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics® Appoints Dr. Karen L. Noblett as Chief Medical Officer
Axonics Announces $20.5 Million Second Closing of its Series C Financing
Axonics Announces $14.5 Million First Close of Series C Financing
Axonics Granted Four U.S. Patents Related to its Implantable Sacral Neuromodulation Technology
Axonics Sacral Neuromodulation System Receives Marketing Approval from Health Canada
Axonics Granted New U.S. Patent Related to its Implantable Neuromodulation Technology
Axonics Sacral Neuromodulation System™ Receives MRI Conditional Labeling
Axonics Announces First Patients Treated in Sacral Neuromodulation Study
Axonics Granted Six U.S. Patents Related to its Implantable Neuromodulation Technology
Axonics Modulation Technologies Announces $38.5 Million Series B Financing